The pharmaceutical and healthcare sector is one of the world’s most vital and innovative.
Against a backdrop of technological change and an increasing and aging population, we partner with our clients to help them achieve their goals, capitalise on opportunities and navigate uncertainty.
Combining deep scientific, technical and strategic knowledge we help our clients by providing the commercial nous, experience and range of services that only a large international professional services firm can offer, to anticipate and deliver innovative and value-enhancing solutions.
Advising Abbvie Inc., on the EU merger control aspects of its US$63 billion acquisition of Allergan
Sterling Pharma Solutions
Advising Sterling Pharma Solutions on its disposal of a UK based pharmaceutical manufacturing business by way of auction sale to GHO Capital
Advising Abcam on its acquisition of Expedeon AG's proteomics and immunology business for €120m
Advising Lupin, on the sale of its entire stake in its Japanese subsidiary, Kyowa Pharmaceutical Industry Co., Ltd. (Kyowa), to Unison Capital for JPY 57.4 billion (c.US$525 million)
Strides Pharma Science Limited
Advising Strides Pharma Science Limited, an Indian listed pharmaceuticals company, on the AU$394 million sale of its entire Australian business, including Arrow Pharmaceuticals, to Arrotex
Advising Genus, a UK listed animal genetics company, on its strategic partnership with Beijing Capital Agribusiness Co. Ltd (BCA) to research, develop, register and market pigs resistant to Porcine Reproductive and Respiratory Syndrome virus (PRRSv) in China
Alan specialises in public and private cross-border mergers and acquisitions, restructurings, joint ventures and partnership matters, acting for international corporates, investment banks and professional services firms.
Natalie is both an experienced Corporate and Mergers & Acquisitions lawyer and an expert in Healthcare, Aged Care, Outsourcing and Privatisations. Natalie is Herbert Smith Freehills’ Sector Lead Partner for Healthcare.